CAS 1116743-46-4
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
6 produits concernés.
SAR125844
CAS :Formule :C25H23FN8O2S2Degré de pureté :%Couleur et forme :SolidMasse moléculaire :550.63091-(6-((6-(4-Fluorophenyl)-[1,2,4]Triazolo[4,3-b]Pyridazin-3-Yl)Thio)Benzo[D]Thiazol-2-Yl)-3-(2-Morpholinoethyl)Urea
CAS :1-(6-((6-(4-Fluorophenyl)-[1,2,4]Triazolo[4,3-b]Pyridazin-3-Yl)Thio)Benzo[D]Thiazol-2-Yl)-3-(2-Morpholinoethyl)UreaDegré de pureté :98+%Masse moléculaire :550.63g/molSAR125884 hydrochlorid (1116743-46-4(free base))
CAS :SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).Formule :C25H23FN8O2S2·HClDegré de pureté :97.95%Couleur et forme :SolidMasse moléculaire :587SAR125844
CAS :SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)Formule :C25H23FN8O2S2Degré de pureté :98.73%Couleur et forme :SolidMasse moléculaire :550.63SAR125844
CAS :<p>SAR125844 is a potent inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR). It has been shown to inhibit tumor growth in animal models and inhibit cell proliferation in cancer cells. SAR125844 has been evaluated in clinical studies for the treatment of patients with prostate cancer, which is resistant to imatinib. The drug was found to be safe and well tolerated at doses up to 800 mg/day. Clinical response rates were observed in some patients who had experienced disease progression while on other therapies. SAR125844 inhibits tumor growth by targeting EGFR, which is an important cellular pathway that promotes cell proliferation and survival.</p>Formule :C25H23FN8O2S2Degré de pureté :Min. 95%Masse moléculaire :550.63 g/mol
![1-(6-((6-(4-Fluorophenyl)-[1,2,4]Triazolo[4,3-b]Pyridazin-3-Yl)Thio)Benzo[D]Thiazol-2-Yl)-3-(2-Mor…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F54%2Fthumb%2FPC108752.jpg&w=3840&q=75)
